Literature DB >> 6227282

In vitro activity of teichomycin compared with those of other antibiotics.

H C Neu, P Labthavikul.   

Abstract

The glycopeptide antibiotic teichomycin had in vitro activity comparable to that of vancomycin against most gram-positive species, and it inhibited methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. It was twofold more active against many S. aureus and S. epidermidis isolates than was vancomycin. Teichomycin had activity comparable to that of vancomycin against Listeria monocytogenes and Streptococcus faecalis. It was generally more active against streptococci than was vancomycin. There were no major differences between minimal inhibitory concentrations and minimal bactericidal concentrations of these drugs. Teichomycin acted synergistically with gentamicin against some bacteria.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6227282      PMCID: PMC185337          DOI: 10.1128/AAC.24.3.425

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Characterization and identification of 95 diphtheroid (group JK) cultures isolated from clinical specimens.

Authors:  P S Riley; D G Hollis; G B Utter; R E Weaver; C N Baker
Journal:  J Clin Microbiol       Date:  1979-03       Impact factor: 5.948

2.  Simplified scheme for routine identification of human Staphylococcus species.

Authors:  W E Kloos; K H Schleifer
Journal:  J Clin Microbiol       Date:  1975-01       Impact factor: 5.948

3.  Comparison of the in vitro activities of teichomycin A2 and vancomycin against staphylococci and enterococci.

Authors:  M H Cynamon; P A Granato
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

4.  Antibiotic-resistant group JK bacteria in hospitals.

Authors:  V J Gill; C Manning; M Lamson; P Woltering; P A Pizzo
Journal:  J Clin Microbiol       Date:  1981-03       Impact factor: 5.948

5.  Cerebrospinal fluid shunt infections with anaerobic diphtheroids (Propionibacterium species).

Authors:  E D Everett; T C Eickhoff; R H Simon
Journal:  J Neurosurg       Date:  1976-05       Impact factor: 5.115

6.  Vancomycin therapy for methicillin-resistant Staphylococcus aureus.

Authors:  T C Sorrell; D R Packham; S Shanker; M Foldes; R Munro
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

7.  Epidemiology of nosocomial infections caused by methicillin-resistant Staphylococcus aureus.

Authors:  R L Thompson; I Cabezudo; R P Wenzel
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

8.  Teichomycins, new antibiotics from Actinoplanes teichomyceticus nov. sp. II. Extraction and chemical characterization.

Authors:  M R Bardone; M Paternoster; C Coronelli
Journal:  J Antibiot (Tokyo)       Date:  1978-03       Impact factor: 2.649

9.  Comparative in vitro study of teichomycin A2.

Authors:  V Fainstein; B LeBlanc; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

10.  Therapeutic granulocyte transfusions for documented infections. A controlled trial in ninety-five infectious granulocytopenic episodes.

Authors:  D J Winston; W G Ho; R P Gale
Journal:  Ann Intern Med       Date:  1982-10       Impact factor: 25.391

  10 in total
  32 in total

1.  A clinical view of vancomycin in 1990.

Authors:  W T Siebert
Journal:  Tex Heart Inst J       Date:  1990

2.  In vitro activities of three semisynthetic amide derivatives of teicoplanin, MDL 62208, MDL 62211, and MDL 62873.

Authors:  F Biavasco; R Lupidi; P E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

3.  Comparison of the agar dilution, tube dilution, and broth microdilution susceptibility tests for determination of teicoplanin MICs.

Authors:  M T Kenny; J K Dulworth; M A Brackman
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

4.  Pharmacokinetics of teicoplanin in hemodialysis patients.

Authors:  D Höffler; P Koeppe; E Naumann; E Lang; F Sörgel
Journal:  Infection       Date:  1991 Sep-Oct       Impact factor: 3.553

5.  Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

Review 6.  Management of listeriosis.

Authors:  H Hof; T Nichterlein; M Kretschmar
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

7.  Poor efficacy of teicoplanin in treatment of deep-seated staphylococcal infections.

Authors:  N Galanakis; H Giamarellou; N Vlachogiannis; C Dendrinos; G K Daikos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-04       Impact factor: 3.267

8.  Problems with the disk diffusion test for detection of vancomycin resistance in enterococci.

Authors:  J M Swenson; B C Hill; C Thornsberry
Journal:  J Clin Microbiol       Date:  1989-09       Impact factor: 5.948

9.  Evaluation of teicoplanin and vancomycin disk susceptibility tests.

Authors:  A L Barry; C Thornsberry; R N Jones
Journal:  J Clin Microbiol       Date:  1986-01       Impact factor: 5.948

10.  Activity of teicoplanin against coagulase-negative staphylococci isolated from patients undergoing continuous peritoneal dialysis.

Authors:  W Brumfitt; J M Hamilton-Miller
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.